Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | MANBA | O00462 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12332279 | 1.00 | LMNA (0.38) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL1301822 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL1984099 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL12018358 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL18596140 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL2756249 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL2367932 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL6676888 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL7147890 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL15678411 | 0.87 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918714-B2 | Human iNKT cell activation using glycolipids with altered glycosyl groups | ACADEMIA SINICA (TW) | 2021-02-16 | — | — | US | disclosed |
| US-20190099486-A1 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS | ACADEMIA SINICA (TW) | 2019-04-04 | — | — | US | disclosed |
| EP-0363344-A1 | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives | G.D. SEARLE & COMPANY (US) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918714-B2 | Human iNKT cell activation using glycolipids with altered glycosyl groups | UGCG, GALK1, B3GAT3 | LMNA 3249/4885CYP1A2 4672/4885THPO 447/4885 |
| US-20190099486-A1 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS | UGCG, GALK1, B3GAT3 | LMNA 3249/4885CYP1A2 4672/4885THPO 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.